Page 9 - Pharmaceutical Holdings News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Complex Regional Pain Syndrome Treatment Market Research Methods that Will Give You Proven Results | Forecast 2021-2027 | CeNeS Pharmaceuticals, Pfizer, King Pharmaceuticals, Bayer, Grnenthal GmbH, Celgene Corporation, Cell Targeting Technologies, Amgen, – KSU

Complex Regional Pain Syndrome Treatment infinityApril 24, 2021 Global Complex Regional Pain Syndrome Treatment Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application Infinity Business Insights published a new report titled “ Complex Regional Pain Syndrome Treatment Market research report which is segmented by Types, By Applications, By End-use, by Region”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period. In 2019, the global Complex Regional Pain Syndrome Treatment Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

United statesAbiogen pharmaGrnenthal gmbInternational players profilesCenes pharmaceuticalsAlgorx pharmaceuticalsEndo pharmaceuticalsCelgene corporationNational institute of nursing researchEli lilly coJustus liebig university giessenKing pharmaceuticalsForest laboratories incLee pharmaceutical holdingsDanish pain research centerBreakdown data

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results News provided by Share this article Share this article NEWARK, N.J., March 17, 2021 /PRNewswire/ Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021. Q2 FY 2021 Consolidated Financial and Operational Highlights Revenue of $1.0 million, generated by Rafael Holdings real estate portfolio, decreased from $1.2 million in the year-ago quarter due, in part, to the sale of its building in Piscataway, NJ. Loss per share of $0.50 compared to a loss per share of $0.08 in the year ago quarter primarily due to a $7.0 million impairment of the company s interest in Altira, as described below.

United statesHoward jonasFordoz pharmaJoshua rabinowitzThird partySarcoma alliance for researchLipomedix pharmaceuticals ltdRafael pharmaceuticalsPrinceton university office of technology licensingRafael holdings incBarer instituteRafael pharmaceuticals incInvestment in rafael pharmaceuticalsRp financeRafael holdingsDrug administration

APAC Pregnancy & Ovulation Testing Market 2020 Competitive Analysis, Segmentation, Industry Highlights and Forecasts Till 2023

APAC Pregnancy & Ovulation Testing Market 2020 Competitive Analysis, Segmentation, Industry Highlights and Forecasts Till 2023
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic of koreaAsia pacificMankind pharma ltdChurch dwight coGregory pharmaceutical holdings incOffice noChurch dwight co incTaidoc technology corporationQuidel corporationMarket research futureMarket researchResearch newswireSee campaignFairhaven healthPiramal enterprises ltd